Tool
Supplement comparison tool
Pick up to 4 knowledge base entries and compare their dosage, price, evidence strength and ratings side by side — you can save or share a link to your selection.
Add to comparison (2/4)
| Category | Choroby i zaburzenia | Choroby i zaburzenia |
| Evidence strength | Strong evidence | Strong evidence |
| Evidence Score | 5/5 | 4/5 |
| User rating | 4.6 (82) | 4.7 (68) |
| Typical dose | — | — |
| Form | — | — |
| Average price | — | — |
| Monthly cost | — | — |
| Time to effects | Slowing the rate of eGFR decline with ACE inhibitors/ARBs or SGLT2 inhibitors can become measurable in clinical observation after a few months to a year, though the effect is usually assessed over a much longer, multi-year horizon, since CKD is a slowly progressive disease. | Densitometry measurements rarely show significant changes before several months — the network meta-analysis indicates that interventions lasting 52 weeks or longer produce more consistent, lasting effects than shorter programs. |
| Who it's for | People with diabetes or hypertension — the two most common causes of CKD worldwide | Perimenopausal and postmenopausal women |